Interviews with Malaria Stakeholders
Topics:
All, Academia, Africa, Charity, Diagnosis, Drug Safety, Education, Entrepreneurship, Equality, Funding, Larvicides, Medicine, Mosquito Nets, New Technologies, Politics, Research & Development
Controlling malaria is a complicated affair. I speak with John Miller of the global health nonprofit PATH on the role of mass drug administration in reducing malaria prevalence.
An interview with Dr Ashley Birkett, Director of PATH’s Malaria Vaccine Initiative. We discuss RTS,S and the global health challenges surrounding it, in terms of vaccine adherence and hesitancy.
Stellar Murumba has been investigating substandard antimalarial drugs. Her work has led to the Kenyan Health Ministry to recall Duo-Cotecxin, a commonly used antimalarial.
Dr Deborah O’Neil is the CEO of Novabiotics, a leading clinical-stage biotechnology company. She talks to me about antibiotic resistance and the future of pharma with so-called ‘personalised medicines’.
Dr Michelle Wykes runs the Molecular Immunology unit at QIMR Berghofer Medical Research Institute and has been focusing on trying to improve the immune system’s response to a malaria infection. We discuss her recent work in malaria research which has been hailed as a breakthrough.
We speak with Professor Jake Baum of Imperial College London. He has been thrust in the spotlight for what the ‘Independent’ is calling a ‘major malaria breakthrough’. His team is working on trying to find a set of compounds that stop mosquitoes from contracting malaria when they bite an infected person.